CADTH Canadian Drug Expert Committee recommendation: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza -- Janssen Inc.) indication: treatment of HIV type 1 (HIV-1) infection
The CADTH Canadian Drug Expert Committee recommends that darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) be reimbursed as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with no known mut...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, July 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) be reimbursed as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with no known mutations associated with resistance to the individual components of D/C/F/TAF, if the following condition is met: condition: the total cost of treatment with D/C/F/TAF should not exceed the total drug-plan cost of treatment with the least costly alternative triple or quadruple single-tablet regimen |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (5 pages) |